1. Gut microbial signature and gut-lung axis: A possible role in the therapy of COVID-19

Ata Mahmoodpoor , Ali Shamekh, Sarvin Sanaie*

BioImpacts. 2022;12(2): 175-177. doi: 10.34172/bi.2021.42

PMCID: PMC8905593 PMID: 35411301 Scopus ID: 85127196118

Article

PDF

Full Text

XML

Cited By:

Original Research

2. The active lung microbiota landscape of COVID-19 patients through the metatranscriptome data analysis

Yang Han , Zhilong Jia* , Jinlong Shi, Weidong Wang*, Kunlun He*

BioImpacts. 2022;12(2): 139-146. doi: 10.34172/bi.2021.23378

PMCID: PMC8905590 PMID: 35411293 Scopus ID: 85127131228

Article

PDF

Suppl 1

Suppl 2

Suppl 3

Full Text

XML

Cited By:

The enrichment of several other pathogens, immunomodulatory probiotics (lactic acid or butyrate producers), and TMV in the COVID-19 group suggests a complex and active lung microbiota disorder.

Submit Your Paper Instructions for Authors Aims and Scope Editorial Board Editorial Policies Publication Ethics Policies Editorial Board Policy Abstracting and Indexing Archive

As a peer-reviewed international open-access journal, BioImpacts publishes articles on basic and translational aspects of pharmaceutical and biomedical sciences.
Acceptance rate: 24%
Publication fee: Free of charge

Indexing/Abstracting Info
PubMed; PubMed Central; Scopus; Science Citation Index Expanded, Google Scholar; SJR ; Essential Science Indicators; Publons; Embase; EBSCOhost; CAS: DOAJ: SHERPA/RoMEO; Ulrich
Member of COPE
Follower of ICMJE
Permission: Creative Commons